annual cash & cash equivalents:
$189.18M-$37.57M(-16.57%)Summary
- As of today (July 27, 2025), NTLA annual cash & cash equivalents is $189.18 million, with the most recent change of -$37.57 million (-16.57%) on December 31, 2024.
- During the last 3 years, NTLA annual cash & cash equivalents has risen by +$65.78 million (+53.30%).
- NTLA annual cash & cash equivalents is now -63.86% below its all-time high of $523.51 million, reached on December 31, 2022.
Performance
NTLA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$126.88M-$62.30M(-32.93%)Summary
- As of today (July 27, 2025), NTLA quarterly cash & cash equivalents is $126.88 million, with the most recent change of -$62.30 million (-32.93%) on March 31, 2025.
- Over the past year, NTLA quarterly cash & cash equivalents has dropped by -$45.10 million (-26.22%).
- NTLA quarterly cash & cash equivalents is now -75.76% below its all-time high of $523.51 million, reached on December 31, 2022.
Performance
NTLA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NTLA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -16.6% | -26.2% |
| 3 y3 years | +53.3% | -4.9% |
| 5 y5 years | +230.6% | +56.7% |
NTLA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -63.9% | +53.3% | -75.8% | +5.3% |
| 5 y | 5-year | -63.9% | +230.6% | -75.8% | +5.3% |
| alltime | all time | -63.9% | +1821.6% | -75.8% | +230.1% |
NTLA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $126.88M(-32.9%) |
| Dec 2024 | $189.18M(-16.6%) | $189.18M(+57.0%) |
| Sep 2024 | - | $120.50M(-7.9%) |
| Jun 2024 | - | $130.85M(-23.9%) |
| Mar 2024 | - | $171.98M(-24.2%) |
| Dec 2023 | $226.75M(-56.7%) | $226.75M(+34.9%) |
| Sep 2023 | - | $168.03M(-2.2%) |
| Jun 2023 | - | $171.81M(-41.6%) |
| Mar 2023 | - | $294.15M(-43.8%) |
| Dec 2022 | $523.51M(+324.2%) | $523.51M(+270.8%) |
| Sep 2022 | - | $141.19M(-4.5%) |
| Jun 2022 | - | $147.78M(+10.8%) |
| Mar 2022 | - | $133.38M(+8.1%) |
| Dec 2021 | $123.41M(-22.9%) | $123.41M(-63.1%) |
| Sep 2021 | - | $334.74M(+157.7%) |
| Jun 2021 | - | $129.88M(-8.2%) |
| Mar 2021 | - | $141.54M(-11.5%) |
| Dec 2020 | $160.02M | $160.02M(-11.0%) |
| Sep 2020 | - | $179.75M(-50.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $361.69M(+346.6%) |
| Mar 2020 | - | $80.99M(+41.5%) |
| Dec 2019 | $57.23M(-2.8%) | $57.23M(+48.9%) |
| Sep 2019 | - | $38.44M(-21.8%) |
| Jun 2019 | - | $49.14M(+4.3%) |
| Mar 2019 | - | $47.10M(-20.0%) |
| Dec 2018 | $58.86M(-82.7%) | $58.86M(-79.9%) |
| Sep 2018 | - | $293.25M(-4.0%) |
| Jun 2018 | - | $305.54M(-6.8%) |
| Mar 2018 | - | $327.78M(-3.8%) |
| Dec 2017 | $340.68M(+24.8%) | $340.68M(+53.3%) |
| Sep 2017 | - | $222.26M(-7.8%) |
| Jun 2017 | - | $241.05M(-6.4%) |
| Mar 2017 | - | $257.55M(-5.7%) |
| Dec 2016 | $273.06M(+260.2%) | $273.06M(-6.0%) |
| Sep 2016 | - | $290.62M(-3.3%) |
| Jun 2016 | - | $300.69M(+368.4%) |
| Mar 2016 | - | $64.19M(-15.3%) |
| Dec 2015 | $75.82M(+670.1%) | $75.82M |
| Dec 2014 | $9.85M | - |
FAQ
- What is Intellia Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Intellia Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Intellia Therapeutics, Inc.?
- What is Intellia Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Intellia Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of NTLA is $189.18M
What is the all time high annual cash & cash equivalents for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high annual cash & cash equivalents is $523.51M
What is Intellia Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, NTLA annual cash & cash equivalents has changed by -$37.57M (-16.57%)
What is Intellia Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NTLA is $126.88M
What is the all time high quarterly cash & cash equivalents for Intellia Therapeutics, Inc.?
Intellia Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $523.51M
What is Intellia Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, NTLA quarterly cash & cash equivalents has changed by -$45.10M (-26.22%)